Skip to main
  1. Stocks
  2. Biohaven Pharmaceutical Hld
  3. Forecast
BHVN

BHVN Stock Forecast & Price Target

BHVN Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 22%
Hold 33%
Sell 11%
Strong Sell 0%

Bulls say

Biohaven is viewed positively because its broad, science-driven pipeline spans high-value areas such as neuroscience, immunology, and oncology, creating multiple shots on goal with differentiated assets like BHV-7000 and the degrader platform. The FDA’s acceptance of the troriluzole filing with a 1Q27 PDUFA and Adcomm is a major near-term catalyst, with the opportunity modeled at about $1.2B to $1.24B and a 40% probability of success, while approval could materially transform the company into a commercial rare-disease story. Longer term, the company’s capital efficiency may improve from the $350M upfront and $50M next year, royalty economics, and reduced burn, supporting a more focused business with meaningful optionality if late-stage readouts are successful.

Bears say

Biohaven is viewed negatively because its value depends on a long-dated, high-risk pipeline while several key programs face regulatory and clinical uncertainty, including the FDA’s partial clinical hold on opakalim and unresolved questions around troriluzole in SCA. The hold delays enrollment and the second-half of 2026 readout for BHV-7000-303, widening a competitive gap versus Xenon while also threatening the timing and economics of the $400M upfront SK deal plus up to $150M in milestones and royalties. At the same time, the company’s broad multi-asset strategy increases R&D and SG&A spend, and the lack of direct clinical data across some phase III programs leaves the stock more exposed to disappointing readouts and regulatory setbacks.

BHVN has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 22% recommend Buy, 33% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biohaven Pharmaceutical Hld and is not a guaranteed prediction by Public.com or investment advice.

BHVN Analyst Forecast & Price Prediction

Get the latest BHVN stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in BHVN

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biohaven Pharmaceutical Hld (BHVN) Forecast

Analysts have given BHVN a Buy based on their latest research and market trends.

According to 9 analysts, BHVN has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biohaven Pharmaceutical Hld (BHVN)


BHVN Analyst Forecast & Price Prediction

Get the latest BHVN stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in BHVN

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover BHVN stock data and trends